Epigenetic and microRNA-dependent control of cytochrome P450 expression: A gap between DNA and protein

Pharmacogenomics

Volumn 10, Issue 7, 2009, Pages 1067-1076

  Gomez, Alvin ^a   Ingelman Sundberg, Magnus ^a  

^a NONE

Author keywords

Cytochrome P450; DNA methylation; Epigenetics; Histone modifications; miRNA

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 5 AZA 2' DEOXYCYTIDINE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; CYTOCHROME P450 2R1; CYTOCHROME P450 2S1; CYTOCHROME P450 2W1; CYTOCHROME P450 3A; DNA; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HISTONE H2A; HISTONE H2B; HISTONE H3; HYPOXIA INDUCIBLE FACTOR 1BETA; MICRORNA; POLYCYCLIC AROMATIC HYDROCARBON; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CARCINOGENICITY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONFERENCE PAPER; DNA METHYLATION; DRUG METABOLISM; DRUG RESPONSE; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; PHARMACOGENETICS; PROMOTER REGION; PROSTATE CANCER; PROTEIN MODIFICATION; PROTEIN PROCESSING; SMOKING; TOXICOGENETICS;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DNA; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICRORNAS; PROTEIN BIOSYNTHESIS;

EID: 70449515534     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.56     Document Type: Conference Paper

References (108)

1. Ingelman-Sundberg M, Sim SC, Gomez A et al.: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526 (2007). ■ In this review, we present that a number of the drug-metabolizing members of the CYP superfamily are potentially under DNA methylation control due to the presence of high density CpG islands in their promoters. (Pubitemid 350116943)
2. Rodríguez-Antona C, Ingelman-Sundberg M: Cytochrome P450 pharmacogenetics and cancer. Oncogene 25, 1679-1691 (2006).
3. Ingelman-Sundberg M, Rodríguez-Antona C: Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philos. Trans. R Soc. Lond. B Biol. Sci. 360, 1563-1570 (2005).
4. Estabrook RW: A passion for P450s (rememberances of the early history of research on cytochrome P450). Drug Metab. Dispos. 31, 1461-1473 (2003).
5. Guengerich FP: Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8, E101-E111 (2006).
6. Fukasawa T, Suzuki A, Otani K: Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J. Clin. Pharm. Ther. 32, 333-341 (2007). (Pubitemid 47063159)
7. Ozdemir V, Kalow W, Tang BK et al.: Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10, 373-388 (2000). (Pubitemid 30433571)
8. Reik W: Stability and flexibility of epigenetic gene regulation in mammalian development. Nature 447, 425-432 (2007).
9. Klose RJ, Bird AP: Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31, 89-97 (2006).
10. Ballestar E, Esteller M: The impact of chromatin in human cancer: linking DNA methylation to gene silencing. Carcinogenesis 23, 1103-1109 (2002). (Pubitemid 34814766)
11. Georgel PT: Role of chromatin/epigenetic modifications on DNA accessibility. Drug News Perspect. 20, 549-556 (2007).
12. Galm O, Esteller M: Beyond genetics - the emerging role of epigenetic changes in hematopoietic malignancies. Int. J. Hematol. 80, 120-127 (2004). (Pubitemid 39201564)
13. Baylin SB, Esteller M, Rountree MR et al.: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10, 687-692 (2001). (Pubitemid 32331576)
14. Holliday R: Epigenetics: a historical overview. Epigenetics 1, 76-80 (2006).
15. Flanagan JM, Wild L: An epigenetic role for noncoding RNAs and intragenic DNA methylation. Genome Biol. 8, 307 (2007).
16. Matzke M, Matzke AJ, Kooter JM: RNA: guiding gene silencing. Science 293, 1080-1083 (2001).
17. Pauler FM, Koerner MV, Barlow DP: Silencing by imprinted noncoding RNAs: is transcription the answer? Trends Genet. 23, 284-292 (2007).
18. Costa FF: Non-coding RNAs: lost in translation? Gene 386, 1-10 (2007).
19. Mattick JS, Makunin IV: Non-coding RNA. Hum. Mol. Genet. 15(Spec. No. 1), R17-R29 (2006).
20. Eddy SR: Non-coding RNA genes and the modern RNA world. Nat. Rev. Genet. 2, 919-929 (2001).
21. Petronis A, Gottesman, II, Kan P et al.: Monozygotic twins exhibit numerous epigenetic differences: clues to twin discordance? Schizophr. Bull. 29, 169-178 (2003). (Pubitemid 36871068)
22. Fraga MF, Ballestar E, Paz MF et al.: Epigenetic differences arise during the lifetime of monozygotic twins. Proc. Natl Acad. Sci. USA 102, 10604-10609 (2005). ■■ Very important finding showing that in genetically similar monozygotic twins, phenotypic differences could occur through epigenetic means.
23. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. (Suppl. 33), 245-254 (2003). (Pubitemid 36278835)
24. Poulsen P, Esteller M, Vaag A et al.: The epigenetic basis of twin discordance in age-related diseases. Pediatr. Res. 61, 38R-42R (2007).
25. Esteller M: Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008).
26. Bateson P, Barker D, Clutton-Brock T et al.: Developmental plasticity and human health. Nature 430, 419-421 (2004).
27. Jiang YH, Bressler J, Beaudet AL: Epigenetics and human disease. Annu. Rev. Genomics Hum. Genet. 5, 479-510 (2004).
28. Ptak C, Petronis A: Epigenetics and complex disease: from etiology to new therapeutics. Annu. Rev. Pharmacol. Toxicol. 48, 257-276 (2008).
29. Heijmans BT, Tobi EW, Stein AD et al.: Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc. Natl Acad. Sci. USA 105, 17046-17049 (2008).
30. Weaver IC, Cervoni N, Champagne FA et al.: Epigenetic programming by maternal behavior. Nat Neurosci. 7, 847-854 (2004).
31. Jirtle RL, Skinner MK: Environmental epigenomics and disease susceptibility. Nat. Rev. Genet. 8, 253-262 (2007).
32. Bestor TH: The DNA methyltransferases of mammals. Hum. Mol. Genet. 9, 2395-2402 (2000).
33. Li E, Bestor TH, Jaenisch R: Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69, 915-926 (1992).
34. Miranda TB, Jones PA: DNA methylation: the nuts and bolts of repression. J. Cell Physiol. 213, 384-390 (2007).
35. Goll MG, Bestor TH: Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 74, 481-514 (2005).
36. Pradhan S, Esteve PO: Mammalian DNA (cytosine-5) methyltransferases and their expression. Clin. Immunol. 109, 6-16 (2003). (Pubitemid 37324737)
37. Imai K, Yamamoto H: Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29, 673-680 (2008).
38. Kawasaki T, Nosho K, Ohnishi M et al.: IGFBP3 promoter methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator phenotype, and p53. Neoplasia 9, 1091-1098 (2007).
39. Ogino S, Kawasaki T, Nosho K et al.: LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int. J. Cancer 122, 2767-2773 (2008).
40. Doerfler W: De novo methylation, long-term promoter silencing, methylation patterns in the human genome, and consequences of foreign DNA insertion. Curr. Top. Microbiol. Immunol. 301, 125-175 (2006).
41. Jass JR: Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50, 113-130 (2007).
42. Raja P, Sanville BC, Buchmann RC et al.: Viral genome methylation as an epigenetic defense against geminiviruses. J. Virol. 82, 8997-9007 (2008).
43. Hochstein N, Muiznieks I, Mangel L et al.: Epigenetic status of an adenovirus type 12 transgenome upon long-term cultivation in hamster cells. J. Virol. 81, 5349-5361 (2007). (Pubitemid 46744444)
44. Sutter D, Westphal M, Doerfler W: Patterns of integration of viral DNA sequences in the genomes of adenovirus type 12-transformed hamster cells. Cell 14, 569-585 (1978). (Pubitemid 9190236)
45. Rountree MR, Bachman KE, Herman JG et al.: DNA methylation, chromatin inheritance, and cancer. Oncogene 20, 3156-3165 (2001).
46. Stirzaker C, Song JZ, Davidson B et al.: Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res. 64, 3871-3877 (2004).
47. Tate PH, Bird AP: Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet. Dev. 3, 226-231 (1993).
48. Caiafa P, Zampieri M: DNA methylation and chromatin structure: the puzzling CpG islands. J. Cell Biochem. 94, 257-265 (2005). (Pubitemid 41420304)
49. Keshet I, Lieman-Hurwitz J, Cedar H: DNA methylation affects the formation of active chromatin. Cell 44, 535-543 (1986). (Pubitemid 16083696)
50. Padjen K, Ratnam S, Storb U: DNA methylation precedes chromatin modifications under the influence of the strain-specific modifier Ssm1. Mol. Cell Biol. 25, 4782-4791 (2005).
51. Tokizane T, Shiina H, Igawa M et al.: Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin. Cancer Res. 11, 5793-5801 (2005). ■ One of the most important papers in the field of P450 epigenetics showing the involvement of epigenetics, particularly DNA methylation, in the regulation of a CYP gene.
52. Denissenko MF, Pao A, Tang M et al.: Preferential formation of benzo[α]pyrene adducts at lung cancer mutational hotspots in P53. Science 274, 430-432 (1996). (Pubitemid 26353359)
53. Shimada T, Martin MV, Pruess-Schwartz D et al.: Roles of individual human cytochrome P-450 enzymes in the bioactivation of benzo(α) pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(α) pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res. 49, 6304-6312 (1989).
54. Shou M, Korzekwa KR, Crespi CL et al.: The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a] pyrene trans-7,8-dihydrodiol. Mol. Carcinog. 10, 159-168 (1994). (Pubitemid 24257511)
55. Whitlock JP Jr.: Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 39, 103-125 (1999).
56. McLemore TL, Adelberg S, Liu MC et al.: Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J. Natl Cancer Inst. 82, 1333-1339 (1990). (Pubitemid 20238488)
57. Pasquini R, Sforzolini GS, Cavaliere A et al.: Enzymatic activities of human lung tissue: relationship with smoking habits. Carcinogenesis 9, 1411-1416 (1988). (Pubitemid 18192730)
58. Denison MS, Pandini A, Nagy SR et al.: Ligand binding and activation of the Ah receptor. Chem. Biol. Interact. 141, 3-24 (2002).
59. Anttila S, Hakkola J, Tuominen P et al.: Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking. Cancer Res. 63, 8623-8628 (2003). ■■ Study showed that the environment, a very important factor in directing epigenetic changes, is instrumental in causing variation in drug response by affecting the expression of a CYP gene.
60. Okino ST, Pookot D, Li LC et al.: Epigenetic inactivation of the dioxin-responsive cytochrome P4501A1 gene in human prostate cancer. Cancer Res. 66, 7420-7428 (2006). (Pubitemid 44289194)
61. Murray GI, Melvin WT, Greenlee WF et al.: Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. Toxicol. 41, 297-316 (2001).
62. Mimura J, Fujii-Kuriyama Y: Functional role of AhR in the expression of toxic effects by TCDD. Biochim. Biophys. Acta 1619, 263-268 (2003).
63. Murray GI, Taylor MC, McFadyen MC et al.: Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res. 57, 3026-3031 (1997).
64. McFadyen MC, Breeman S, Payne S et al.: Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J. Histochem. Cytochem. 47, 1457-1464 (1999).
65. McFadyen MC, Cruickshank ME, Miller ID et al.: Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br. J. Cancer 85, 242-246 (2001).
66. Gunes A, Dahl ML: Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 9, 625-637 (2008). (Pubitemid 351803920)
67. Quattrochi LC, Tukey RH: The human cytochrome CYP1A2 gene contains regulatory elements responsive to 3-methylcholanthrene. Mol. Pharmacol. 36, 66-71 (1989).
68. Cross SH, Bird AP: CpG islands and genes. Curr. Opin. Genet. Dev. 5, 309-314 (1995).
69. Jones PA, Takai D: The role of DNA methylation in mammalian epigenetics. Science 293, 1068-1070 (2001).
70. Larsen F, Gundersen G, Lopez R et al.: CpG islands as gene markers in the human genome. Genomics 13, 1095-1107 (1992).
71. Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes. J. Mol. Biol. 196, 261-282 (1987).
72. Takai D, Jones PA: Comprehensive ana lysis of CpG islands in human chromosomes 21 and 22. Proc. Natl Acad. Sci. USA 99, 3740-3745 (2002).
73. Ghotbi R, Gomez A, Milani L et al.: Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J. 9(3), 208-217 (2009).
74. Karlgren M, Gomez A, Stark K et al.: Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem. Biophys. Res. Commun. 341, 451-458 (2006).
75. Gomez A, Karlgren M, Edler D et al.: Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics 8, 1315-1325 (2007). ■ CYP2W1 has been shown to be expressed in the developing embryo and is re-expressed in colon tumor through aberrant changes in DNA methylation. (Pubitemid 350162848)
76. Oneta CM, Lieber CS, Li J et al.: Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J. Hepatol. 36, 47-52 (2002). (Pubitemid 34234015)
77. Jones SM, Boobis AR, Moore GE et al.: Expression of CYP2E1 during human fetal development: methylation of the CYP2E1 gene in human fetal and adult liver samples. Biochem. Pharmacol. 43, 1876-1879 (1992).
78. Vieira I, Pasanen M, Raunio H et al.: Expression of CYP2E1 in human lung and kidney during development and in full-term placenta: a differential methylation of the gene is involved in the regulation process. Pharmacol. Toxicol. 83, 183-187 (1998). (Pubitemid 28512134)
79. Dannenberg LO, Edenberg HJ: Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 7, 181 (2006).
80. Nan X, Ng HH, Johnson CA et al.: Transcriptional repression by the methyl- CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393, 386-389 (1998). (Pubitemid 28269714)
81. Staynov DZ: The controversial 30 nm chromatin fibre. Bioessays 30, 1003-1009 (2008).
82. Luger K, Mäder AW, Richmond RK, Sargent DF, Richmond TJ: Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389, 251-260 (1997). (Pubitemid 27406632)
83. Schones DE, Zhao K: Genome-wide approaches to studying chromatin modifications. Nat. Rev. Genet. 9, 179-191 (2008).
84. Strahl BD, Allis CD: The language of covalent histone modifications. Nature 403, 41-45 (2000).
85. Happel N, Stoldt S, Schmidt B et al.: M-phase-specific phosphorylation of histone H1.5 at threonine 10 by GSK-3. J. Mol. Biol. 386(2), 339-350 (2008).
86. Wu J, Huen MS, Lu LY et al.: Histone ubiquitination associates with BRCA1- dependent DNA damage response. Mol. Cell Biol. 29, 849-860 (2009).
87. Nathan D, Ingvarsdottir K, Sterner DE et al.: Histone sumoylation is a negative regulator in Saccharomyces cerevisiae and shows dynamic interplay with positive-acting histone modifications. Genes Dev. 20, 966-976 (2006).
88. Wang Y, Li M, Stadler S et al.: Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J. Cell Biol. 184(2), 205-213 (2009).
89. Lafon-Hughes L, Di Tomaso MV, Mendez-Acuna L et al.: Chromatinremodelling mechanisms in cancer. Mutat. Res. 658, 191-214 (2008).
90. Cosgrove MS, Wolberger C: How does the histone code work? Biochem. Cell Biol. 83, 468-476 (2005).
91. Jenuwein T, Allis CD: Translating the histone code. Science 293, 1074-1080 (2001).
92. Schnekenburger M, Peng L, Puga A: HDAC1 bound to the CYP1A1 promoter blocks histone acetylation associated with Ah receptor-mediated trans-activation. Biochim. Biophys. Acta 1769, 569-578 (2007). (Pubitemid 47404659)
93. Wei YD, Tepperman K, Huang MY et al.: Chromium inhibits transcription from polycyclic aromatic hydrocarbon-inducible promoters by blocking the release of histone deacetylase and preventing the binding of p300 to chromatin. J. Biol. Chem. 279, 4110-4119 (2004).
94. Li Y, Cui Y, Hart SN, Klaassen CD, Zhong X: Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation. Mol. Pharmacol. 75(5), 1171-1179 (2009). ■■ The developmental switch in the expression of Cyp3 members in mice was shown in this study to be due to histone modification changes in a locus-specific manner while DNA methylation did not change.
95. Ambros V: The functions of animal microRNAs. Nature 431, 350-355 (2004).
96. Wienholds E, Plasterk RH: MicroRNA function in animal development. FEBS Lett. 579, 5911-5922 (2005).
97. Tsuchiya Y, Nakajima M, Takagi S et al.: MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 66, 9090-9098 (2006). (Pubitemid 44521128)
98. Kalscheuer S, Zhang X, Zeng Y et al.: Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone. Carcinogenesis 29, 2394-2399 (2008). ■■ The expression pattern of miRNAs in carcinogenesis could potentially lead to the expression of CYPs and even promote the carcinogenic process.
99. Schembri F, Sridhar S, Perdomo C et al.: MicroRNAs as modulators of smokinginduced gene expression changes in human airway epithelium. Proc. Natl Acad. Sci. USA 106(7), 2319-2324 (2009).
100. Gonzalez FJ: CYP3A4 and pregnane X receptor humanized mice. J. Biochem. Mol. Toxicol. 21, 158-162 (2007).
101. Takagi S, Nakajima M, Mohri T et al.: Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J. Biol. Chem. 283, 9674-9680 (2008).
102. Mu YM, Yanase T, Nishi Y et al.: A nuclear receptor system constituted by RAR and RXR induces aromatase activity in MCF-7 human breast cancer cells. Mol. Cell Endocrinol. 166, 137-145 (2000).
103. (2) gene in head and neck. Carcinogenesis Clin. Cancer Res. 10, 1733-1742 (2004).
104. Bovenzi V, Momparler RL: Antineoplastic action of 5-aza-2′- deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor a genes in breast carcinoma cells. Cancer Chemother. Pharmacol. 48, 71-76 (2001). (Pubitemid 32662439)
105. Tsuchiya Y, Nakajima M, Yokoi T: Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 227, 115-124 (2005). (Pubitemid 41174580)
106. Westberry JM, Prewitt AK, Wilson ME: Epigenetic regulation of the estrogen receptor a promoter in the cerebral cortex following ischemia in male and female rats. Neuroscience 152, 982-989 (2008).
107. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee www.cypalleles.ki.se
108. microRNA.org: a resource for predicted microRNA targets and expression www.microrna.org